m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05076
 [1], [2]
Non-coding RNA CircBACH2 miR-944  lncRNA       miRNA   circRNA Indirect Enhancement m6A modification TFAP2A TFAP2A HNRNPC : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) READER
 Regulator Info 
m6A Target Transcription factor AP-2-alpha (TFAP2A)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_BACH2 circRNA View Details
Regulated Target hsa-miR-944 View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary Analysis and validation of m6A regulatory network: a novel Circ_BACH2/hsa-miR-944/HNRNPC axis in breast cancer progression.HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated Transcription factor AP-2-alpha (TFAP2A)/DDR1 axis
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
In-vitro Model
 EO771 Malignant neoplasms of the mouse mammary gland Mus musculus CVCL_GR23
EMT6 Malignant neoplasms of the mouse mammary gland Mus musculus CVCL_1923
4T1.2 Malignant neoplasms of the mouse mammary gland Mus musculus CVCL_GR32
NMuMG
 N.A. Mus musculus CVCL_0075
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [3]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [4]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression. J Transl Med. 2021 Dec 24;19(1):527. doi: 10.1186/s12967-021-03196-4.
Ref 2 HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis. Mol Med. 2023 Aug 1;29(1):103. doi: 10.1186/s10020-023-00696-5.
Ref 3 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015